华蟾素联合顺铂腔内注射治疗恶性胸腹水

目的：探讨华蟾素联合顺铂腔内注射治疗恶性胸腹水的疗效。方法：将66例恶性胸腹水患者随机分为2组，试验组33例抽取胸腹水后腔内灌注华蟾素20mL和顺铂60mg，每周1次，连续2—4周。对照组33例采用单药顺铂60mg腔内灌注。结果：试验组22例恶性胸水患者治疗有效率86．4％；11例恶性腹水患者治疗有效率72．7％；试验组治疗恶性胸腹水总有效率81．8％，KPS评分提高21例，稳定10例，降低2例。对照组21例恶性胸水患者的有效率为52．4％；12例恶性腹水患者的有效率为41．7％；对照组治疗恶性胸腹水总有效率为48．5％，KPS评分提高9例，稳定12例，降低12例。2组疗效比较，试验组优于对照组（P〈0．05），毒性反应更小（P〈0．05）。结论：华蟾素联合顺铂腔内注射治疗恶性胸腹水疗效满意，副作用小，值得临床推广应用。

Intrapericardial infusion of Huachansu and cisplatin in the treatment of the malignant pleural effusion and ascites

Objective:To observe the effect of intrapericardial infusion of Huachansu and cisplatin in the treatment of the malignant pleural effusion and ascites.Methods:The sixty six patients were randomly divided into two groups.Patients in the treatment group(n=33) were infused with 20 mL of Huachansu injection and 60 mg of cisplatin intrapericardially once a week and the treatment lasted for 2-4 weeks.Patients in the control group (n=33) were infused with 60 mg of cisplatin intrapericardially.Results:For the treatment group,the response rate(complete response+partial response) was 86.4% in 22 cases with malignant pleural effusion and 72.7%(8/11) in 11 cases with malignant ascites.The total response rate was 81.8%(27/33).The living qualities were improved in 21 cases,stable in 10 cases,and decreased in 2 cases.For the control group,the response rate(complete response+partial response) was 52.4% in 21 cases with malignant pleural effusion and 41.7% in 12 cases with malignant ascites.The total response rate was 48.5%.The living qualities were improved in 9 cases,stable in 12 cases,and decreased in 12 cases.The response rate was significantly higher and the toxic reaction was significantly lower in the treatment group than that in the control group(P<0.05).Conclusion:Intrapericardial infusion of Huachansu injection plus cisplatin achieves satisfactory effects in the treatment of malignant pleural effusion and ascites and has less side effects.It is worthy of clinical application.